Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide. Despite the success over recent years in the treatment of NSCLC it has not yet been able to achieve good long-term survival. The development of immune checkpoint inhibitors has altered the landscape of treatment...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: K. K. Laktionov, K. A. Sarantseva, D. I. Yudin, V. V. Breder, E. V. Reutova, K. P. Laktionov
Formaat: Artigo
Taal:Russo
Gepubliceerd in: Remedium Group LLC 2019-12-01
Reeks:Медицинский совет
Onderwerpen:
immunotherapy
non-small cell lung cancer
checkpoint inhibitors
nivolumab
Online toegang:https://www.med-sovet.pro/jour/article/view/5036
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items